Day 3 *AGENDA IS SUBJECT TO CHANGE*Wednesday, 25 March 2026

QPMind is a new kind of biotech company – the first biotech company to apply the combination of AI with Quantitative Systems Pharmacology (QSP), a sophisticated method of biological modeling, to drive the drug discovery process de novo with a platform approach for central nervous system (CNS) diseases. The company was founded in 2023 by experienced entrepreneurs in biotech who know drug discovery, AI for drug discovery and QSP modeling, and who have significant prior work to draw upon for QPMind’s initial platform.

QPMind’s vision is to build an organically growing QSP model base that can be applied to all aspects of drug discovery and development to reduce the cost and increase the success rate of drugs in the clinic by a factor of five. The growing model base combined with AI and experts in the field acts as a “super mind” for drug discovery, delivering an efficiency like no prior approach.

At Cogitars, we're transforming the future of drug development by reimagining how clinical trials are designed, conducted, and optimized. We are pioneers in adaptive clinical trial methodologies and Bayesian designs, bringing cutting-edge statistical solutions to biotech and pharmaceutical companies worldwide. Our mission is to accelerate the journey of life-saving therapies from laboratory to patient by making clinical trials smarter, faster, and more efficient. We specialize in the critical challenges of early phase trials (phase I and II), where traditional approaches fall short. Through innovative trial designs, we help our partners minimize patient risk, reduce costs and make more informed decisions at every stage of development. We don't just provide theoretical frameworks—we deliver practical, implementable solutions that span from technical execution to protocol writing and regulatory negotiations. Our team understands that every compound is unique and that novel drugs need tailored designs to maximise success. Our vision extends beyond individual trials. Through evidence synthesis and strategic biostatistical consulting, we help companies optimally prepare for subsequent development phases, building on accumulated knowledge to strengthen their entire development pipeline. At Cogitars, we believe that better statistics means better medicine. We're not just supporting clinical trials—we're revolutionizing how they're done.

Redwood AI supports small-molecule research and manufacturing through an AI-driven software platform that automates the evaluation of synthetic routes and early chemistry decisions. The system is designed to surface practical considerations that influence how a compound moves from discovery toward development, while allowing human oversight where expert judgment is needed.

The platform generates and compares multiple synthetic possibilities and links them to operational factors that often determine whether a route can succeed in practice. These include material availability, supply-chain reliability, process safety, and compatibility with laboratory or plant equipment. By connecting automated predictions with real-world constraints, the platform helps teams understand the downstream implications of different strategies before committing resources.

Redwood AI originated as a spin-off drawing on work from the University of British Columbia, McMaster University, and Stanford University, combining expertise in synthetic chemistry, applied machine learning, and data engineering. We work with pharmaceutical and biotechnology groups, CDMOs, academic laboratories, and non-profit organizations that require structured chemical analysis without maintaining their own cheminformatics infrastructure.

Engagements typically involve automated comparative evaluation of route options, focused assessments of reaction or impurity risks, and development of prioritization frameworks that integrate into existing client workflows. Our aim is to provide clear, technically grounded outputs that support project decisions, strengthen chemistry processes, and facilitate effective handoffs between discovery, development, and external manufacturing partners.

Biorevert was founded with over 25 years of scientific achievements to be translated into cancer reversion therapies. Based on this, we developed our drug discovery platform that can identify novel targets and their mechanism of actions using AI and computational analysis. Despite huge unmet need, there is no specific solution for treating cancer. We believe that our platform technology can fulfill the unmet needs in new drug development market and will be the absolute solution for cancer patients.